MedTrace Logo

Inhaled Cannabis for Treatment of PTSD

NCT07224698 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2025-12-10

No results posted yet for this study

Summary

The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

Conditions

  • Post Traumatic Stress Disorder PTSD

Interventions

DRUG

High THC Cannabis

dried flower of the Cannabis sativa or indica plant with high (18-22%) THC content

DRUG

Placebo cannabis

Placebo contains \<1% THC

Sponsors & Collaborators

  • Changemark Research + Evaluation Ltd.

    collaborator UNKNOWN

  • Multidisciplinary Association for Psychedelic Studies

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-06-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07224698 on ClinicalTrials.gov